TMCnet News

McKesson and Epic Settle Patent Infringement Litigation
[March 04, 2013]

McKesson and Epic Settle Patent Infringement Litigation

SAN FRANCISCO --(Business Wire)--

McKesson Corporation and Epic Systems Corporation have settled their longstanding patent infringement litigation involving McKesson's U.S. patent #6,757,898 and Epic's MyChart software.

Under terms of the settlement, McKesson agreed to grant Epic a license to the patent for the benefit of Epic and its customers. In exchange, Epic agreed that it will no longer contest the validity of the patent, allowing McKesson and Epic to return to normalcy in their relationship going forward. The parties also agreed to dismiss all pending claims and counterclaims and end any further litigation and appeals.

Executives from both parties recognized the settlement as one that will benefit the healthcare industry in general, and allow both partiesto focus on the needs of their customers.

"We're delighted to have settled this litigation with McKesson." said Carl Dvorak, chief operating officer, Epic Systems Corporation.

"We look forward to reestablishing our prior relationship and exploring new opportunities to serve our mutual customers," echoed Jeff Felton, president of McKesson's RelayHealth business. "Both companies will benefit by putting this litigation behind us."

About McKesson Corporation

McKesson Corporation, currently ranked 14th on the FORTUNE 500, is a healthcare services and information technology company dedicated to making the business of healthcare run better. We partner with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. For more information, visit us at

[ Back To's Homepage ]